Rhythm Pharmaceuticals, Inc.
RYTM
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) dā¦ read more
Healthcare
Biotechnology
8 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$101.06
Price-0.73%
-$0.74
1Y
Price
Market Cap
$6.932b
Mid
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-61.8%
EBITDA Margin-69.2%
Net Profit Margin-74.8%
Free Cash Flow Margin-61.8%
EBITDA Margin-69.2%
Net Profit Margin-74.8%
Free Cash Flow MarginRevenue
$239.918m
+26.4%
1y CAGR+46.8%
3y CAGR+92.0%
5y CAGREarnings
-$205.346m
-4.5%
1y CAGR-7.0%
3y CAGR-5.7%
5y CAGREPS
-$3.11
-
1y CAGR-2.4%
3y CAGR+0.4%
5y CAGRBook Value
$217.301m
$437.266m
Assets$219.965m
Liabilities$3.682m
DebtDebt to Assets
0.8%
-
Debt to EBITDAFree Cash Flow
-$150.486m
-29.0%
1y CAGR-5.0%
3y CAGR+2.1%
5y CAGRNo items found.
Press Releases
Statements and updates from the company